Alzheimer's & Dementia-Diagnosis, Assessment & Disease Monitoring

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring is a quarterly open access journal published by Wiley on behalf of the Alzheimer's Association, founded in 2015 as an online companion to Alzheimer's & Dementia, devoted to the discovery, development and validation of tools for diagnosing and monitoring Alzheimer's disease and related dementias, with a 2025 Journal Impact Factor of 4.9.《阿尔茨海默病与痴呆：诊断、评估与疾病监测》（Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring）是（Wiley）代表阿尔茨海默病协会出版的开放获取季刊，2015 年作为《阿尔茨海默病与痴呆》（Alzheimer's & Dementia）的在线姊妹刊创刊，致力于痴呆诊断与病程监测工具的开发与验证，2025 年期刊影响因子为 4.9。

Scope

• The mission of the journal is to bridge the knowledge gaps across a wide range of bench-to-bedside investigation into Alzheimer's disease and related dementias.刊物宗旨是弥合阿尔茨海默病及相关痴呆从基础到临床各层面研究的知识缺口。
• It publishes studies in behavior, biochemistry, genetics, molecular biology, pharmacology, physiology, protein chemistry, neurology, neuropathology, psychiatry, geriatrics, neuropsychology, epidemiology, sociology, health services research, health economics, political science and public policy.发表行为学、生物化学、遗传学、分子生物学、药理学、生理学、蛋白质化学、神经病学、神经病理学、精神病学、老年医学、神经心理学、流行病学、社会学、卫生服务研究、卫生经济学、政治学与公共政策等领域的研究。
• The journal emphasizes interdisciplinary and integrative or translational work on etiology, risk factors, early detection, disease modifying interventions, prevention of dementia and applications of new technologies in health services.刊物侧重跨学科及整合性、转化性研究，主题涵盖病因、风险因素、早期检测、疾病修正干预、痴呆预防以及新技术在卫生服务中的应用。
• Its core concentration is the discovery, development and validation of assays, instruments and technologies that can facilitate accurate detection of dementia in its various forms and stages.核心聚焦有助于各类痴呆在不同形式与阶段实现准确检测的检测方法、仪器与技术的发现、开发与验证。
• Promising biomarkers of particular interest range from gene expression and proteomic markers to imaging, cognitive and functional markers of disease progression or treatment response.尤受关注的是从基因表达与蛋白质组学标志物，到疾病进展或治疗反应的成像、认知与功能标志物。
• Research is limited to human studies and covers methodological advances and conceptual challenges in the diagnosis, prognosis and disease management of Alzheimer's disease and related dementias.研究仅限人类研究，覆盖阿尔茨海默病及相关痴呆在诊断、预后与疾病管理上的方法学进展与概念挑战。
• Article types include research articles, short reports that also carry negative results and clinical trial information, invited reviews and perspectives, policy forums, letters to the editor and research news.稿件类型包括研究论文、短篇报告（含阴性结果与临床试验信息）、邀稿综述与展望、政策论坛、通信及研究新闻。

History

• The Alzheimer's Association launched the journal in 2015 as an open access online companion to Alzheimer's & Dementia, and Volume 1, issue 1 appeared in March 2015.刊物于 2015 年由阿尔茨海默病协会创办，作为《阿尔茨海默病与痴呆》的开放获取在线姊妹刊，同年 3 月出版第 1 卷第 1 期。^[1]
• From 2015 to 2019 the journal was published by Elsevier, with each early issue numbered as its own volume, and since 2020 it has been published by Wiley on behalf of the Alzheimer's Association.2015 年至 2019 年刊物由（Elsevier）出版，早期各期单独编卷；2020 年起改由（Wiley）代表协会出版。
• Peter J. Snyder served as founding editor-in-chief for eight years, and with the start of Volume 14 in 2022 Liana G. Apostolova took over as editor-in-chief.（Peter J. Snyder）担任创刊主编八年后，自 2022 年第 14 卷起由（Liana G. Apostolova）接任主编。^[2]
• The journal appears quarterly, and since the move to Wiley each year forms a single volume, with Volume 18 published in 2026.刊物按季出版，2020 年起每年合为一卷，2026 年出版第 18 卷。
• It is a gold open access journal, with an article publication charge of 2670 US dollars, a 50 percent discount for members of the International Society to Advance Alzheimer's Research and Treatment, and CC BY-NC or CC BY-NC-ND licenses.刊物为金色开放获取，文章处理费 2670 美元，国际阿尔茨海默病研究与治疗学会会员可享五折优惠，论文采用 CC BY-NC 或 CC BY-NC-ND 许可。
• The 2025 Journal Impact Factor is 4.9, after 4.4 in 2024, and in the 2025 JCR the journal ranks in the first quartile of both clinical neurology and neurosciences.2025 年期刊影响因子为 4.9，2024 年为 4.4；2025 年 JCR 中刊物在临床神经病学与神经科学两个类别均列一区。

Editors

• The Editor-in-Chief is Liana G. Apostolova, professor at the Indiana University School of Medicine and associate dean for Alzheimer's disease research, whose work centers on early-onset Alzheimer's disease and on imaging and genetic biomarkers.主编为（Liana G. Apostolova），印第安纳大学医学院教授兼阿尔茨海默病研究协理院长，研究方向为早发阿尔茨海默病及影像与遗传学生物标志物。
• Deputy Editors are Peter J. Snyder of the University of Rhode Island, the founding editor-in-chief, and Henrik Zetterberg of the University of Gothenburg in Sweden.副主编为罗得岛大学的（Peter J. Snyder）（创刊主编）与瑞典哥德堡大学的（Henrik Zetterberg）。
• Eleven section editors cover neuropsychology, imaging, genetics, epidemiology, biostatistics and artificial intelligence, working at Harvard, Indiana University, UCLA, the Karolinska Institute, Simon Fraser University and the University of Sao Paulo.刊物设 11 名栏目编辑，分管神经心理学、影像、遗传学、流行病学、生物统计与人工智能等方向，来自哈佛、印第安纳大学、加州大学洛杉矶分校、卡罗林斯卡学院、西蒙弗雷泽大学与圣保罗大学等机构。
• Senior associate editors sit at Rutgers University, the Institut de Recerca Sant Pau in Barcelona and the Chinese University of Hong Kong, while associate editors span Australia, Singapore, Sweden and Israel, and a statistical editor oversees methodology.高级副编辑来自罗格斯大学、巴塞罗那圣保罗研究所与香港中文大学，副编辑分布于澳大利亚、新加坡、瑞典与以色列，并设统计学编辑主管方法学。
• Peer review is single blind, with a minimum of two independent expert reviewers and the handling editor responsible for the final decision.同行评审采用单盲方式，研究论文通常送交至少两名独立专家审稿，编辑对录用决定负最终责任。
• Research articles are submitted through Editorial Manager without a submission fee, while reviews and perspectives are invitation only, and every manuscript must include a Research in Context summary.研究论文经（Editorial Manager）提交且不收投稿费，综述与展望仅限邀稿，所有稿件均须附研究背景综述。